Rayzebio, Inc.
Clinical trials sponsored by Rayzebio, Inc., explained in plain language.
-
New hope for gut cancer patients who failed standard therapy
Disease control Recruiting nowThis study tests a new drug called RYZ101 in people with advanced neuroendocrine tumors of the gut or pancreas that have grown after prior treatment with a standard radioactive therapy. The goal is to see if RYZ101 can slow tumor growth better than other available treatments. Abo…
Phase: PHASE3 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
Radioactive drug RYZ401 targets Hard-to-Treat tumors in first human trial
Disease control Recruiting nowThis early-stage study tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The main goals are to find the safest dose and schedule, and to see if the drug can shrink tumors. About 10…
Phase: PHASE1 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New 'See and Treat' combo targets Hard-to-Treat liver cancer
Disease control Recruiting nowThis study tests a pair of drugs: one that lights up cancer cells on scans (RYZ811) and another that delivers radiation directly to those cells (RYZ801). It is for adults with a type of liver cancer (GPC3-positive) that cannot be removed by surgery and has worsened after one prio…
Phase: PHASE1, PHASE2 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated May 11, 2026 20:50 UTC